<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907370</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-ISS-CO291</org_study_id>
    <nct_id>NCT04907370</nct_id>
  </id_info>
  <brief_title>PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma</brief_title>
  <official_title>Toripalimab Combined With Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multi-center, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, multi-center, randomized controlled trial, with the purpose to evaluate&#xD;
      the therapeutic efficacy and safety of PD-1 blockade (toripalimab) combined with the&#xD;
      de-intensification radical chemoradiotherapy sparing concurrent cisplatin (i.e., toripalimab&#xD;
      plus induction chemotherapy followed by radiotherapy alone) in high-risk locoregionally&#xD;
      advanced nasopharyngeal carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 3, multi-center, randomized controlled trial plans to enroll 494 patients with&#xD;
      newly-diagnosed, pathologically-proven, untreated locoregionally advanced nasopharyngeal&#xD;
      carcinoma (LANPC) at high-risk of distant metastasis (T4N1 and T1-4N2-3, according to&#xD;
      American Joint Committee on Cancer [AJCC]/Union for International Cancer Control [UICC] 8th&#xD;
      edition clinical staging system). Patients will receive 3 cycles of induction chemotherapy&#xD;
      (IC; gemcitabine-cisplatin regimen) followed by 1) experimental arm (de-intensification&#xD;
      group): intensity-modulated radiotherapy (IMRT) alone or 2) control arm (standard group): 2&#xD;
      cycles of concurrent cisplatin plus IMRT (CCRT). For both of the two arms, toripalimab will&#xD;
      be adopted on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the&#xD;
      end of IMRT, with the first and last 3 cycles of toripalimab administrated along with IC and&#xD;
      CCRT/IMRT, respectively. After three weeks of the completion of IMRT, adjuvant toripalimab&#xD;
      will be used every 3 weeks for 11 cycles, and therefore the entire treatment process is&#xD;
      expected to last for one year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free survival (FFS)</measure>
    <time_frame>3-year</time_frame>
    <description>Failure-free survival is measured from day of diagnosis until treatment failure, death from any cause, or last follow-up visit, whichever occurred first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3-year</time_frame>
    <description>Overall survival is measured from day of diagnosis until death due to any cause or the latest known date alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional failure-free survival (LRFFS)</measure>
    <time_frame>3-year</time_frame>
    <description>Locoregional failure-free survival is measured from day of diagnosis until local or regional recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant failure-free survival (DFFS)</measure>
    <time_frame>3-year</time_frame>
    <description>Distant failure-free survival is measured from day of diagnosis until distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of investigator-reported adverse events (AEs)</measure>
    <time_frame>3-year</time_frame>
    <description>Analysis of investigator-reported adverse events (AEs) are based on treatment-related AEs (trAEs) and immune-related AEs (irAEs), and all-grade AEs and grade 3-4 AEs. AEs are evaluated by investigators according to the Common Terminology Criteria for Adverse Events, version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of patient-reported adverse events (AEs)</measure>
    <time_frame>3-year</time_frame>
    <description>Analysis of patient-reported adverse events (AEs) are based on treatment-related AEs (trAEs) and immune-related AEs (irAEs), and all-grade AEs and grade 3-4 AEs. AEs are evaluated by patients themselves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL): questionnaire</measure>
    <time_frame>week 1, 20, 40, 64</time_frame>
    <description>Changes in QoL of participants from initial treatment to 6 months after the completion of 6 cycles adjuvant PD-1 blocking antibody. QoL is evaluated with the use of (1) the head-and-neck-specific module (H&amp;N35) of the Quality of Life Questionnaire-Core 30 module (QLQ-C30), which is established by European Organization for Research and Treatment of Cancer (EORTC) and (2) the general and head-and-neck-specific module of the evaluation tool developed by the Functional Assessment of Cancer Therapy (FACT). Scores for the module range of H&amp;N35 QLQ-C30 from 0 to 100, with higher scores indicating better functioning or well-being or higher symptom burden (scales measuring symptom burden were reverse-scored to facilitate presentation)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation between pre-treatment PD-L1 expression level and FFS</measure>
    <time_frame>3-year</time_frame>
    <description>Pre-treatment PD-L1 expression level of tumor cell is evaluated centrally by means of immunohistochemical testing. This is a single assessment with only one unit of measure, since the correlation is aimed to be roughly categorized into positive and negative.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation between pre-treatment PD-L1 expression level and OS</measure>
    <time_frame>3-year</time_frame>
    <description>Pre-treatment PD-L1 expression level of tumor cell is evaluated centrally by means of immunohistochemical testing. This is a single assessment with only one unit of measure, since the correlation is aimed to be roughly categorized into positive and negative.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation between the percentage of tumor-infiltrating lymphocytes (TILs) and PFS</measure>
    <time_frame>3-year</time_frame>
    <description>TILs are lymphoid cells (T cells) that infiltrate solid tumors (intra-tumoral TILs) and stroma (stromal TILs), which play an important role in the tumor microenvironment. This is a single assessment with only one unit of measure, since the correlation is aimed to be roughly categorized into positive and negative.</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation between the percentage of tumor-infiltrating lymphocytes (TILs) and OS</measure>
    <time_frame>3-year</time_frame>
    <description>TILs are lymphoid cells (T cells) that infiltrate solid tumors (intra-tumoral TILs) and stroma (stromal TILs), which play an important role in the tumor microenvironment. This is a single assessment with only one unit of measure, since the correlation is aimed to be roughly categorized into positive and negative.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate failure-free survival in the subgroup of age at diagnosis (year)</measure>
    <time_frame>3-year</time_frame>
    <description>Subgroup analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate failure-free survival in the subgroup of gender (male and female)</measure>
    <time_frame>3-year</time_frame>
    <description>Subgroup analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate failure-free survival in the subgroup of plasma Epstein-Barr virus DNA level</measure>
    <time_frame>3-year</time_frame>
    <description>Subgroup analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate failure-free survival in the subgroup of clinical stage</measure>
    <time_frame>3-year</time_frame>
    <description>Subgroup analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">494</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Toripalimab Combined with Induction Chemotherapy Followed by Radiotherapy Alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles; gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by intensity-modulated radiotherapy (IMRT; 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day) alone. PD-1 blockade toripalimab (240 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone. The first and last 3 cycles of toripalimab are administrated concurrently with IC and IMRT, respectively. After 3 weeks of the completion of IMRT, adjuvant toripalimab (240 mg per cycle) will begin every 3 weeks for 11 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toripalimab Combined with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All participants will receive induction chemotherapy (IC; every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1) followed by concurrent chemoradiotherapy (CCRT; every 3 weeks × 2 cycles of cisplatin + IMRT 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day). PD-1 blockade toripalimab (240 mg per cycle) will start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of CCRT, involving the whole-course of IC + CCRT. The first and last 3 cycles of toripalimab are administrated concurrently with IC and CCRT, respectively. After 3 weeks of the completion of CCRT, adjuvant toripalimab (240 mg per cycle) will begin every 3 weeks for 11 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 blocking antibody</intervention_name>
    <description>IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.&#xD;
IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.&#xD;
Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1</description>
    <arm_group_label>Toripalimab Combined with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy</arm_group_label>
    <arm_group_label>Toripalimab Combined with Induction Chemotherapy Followed by Radiotherapy Alone</arm_group_label>
    <other_name>PD-1 Blockade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles</description>
    <arm_group_label>Toripalimab Combined with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy</arm_group_label>
    <arm_group_label>Toripalimab Combined with Induction Chemotherapy Followed by Radiotherapy Alone</arm_group_label>
    <other_name>GEM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (80mg/m2)</intervention_name>
    <description>Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles</description>
    <arm_group_label>Toripalimab Combined with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy</arm_group_label>
    <arm_group_label>Toripalimab Combined with Induction Chemotherapy Followed by Radiotherapy Alone</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (100mg/m2)</intervention_name>
    <description>Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles</description>
    <arm_group_label>Toripalimab Combined with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy</arm_group_label>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-modulated radiotherapy</intervention_name>
    <description>Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day</description>
    <arm_group_label>Toripalimab Combined with Induction Chemotherapy Followed by Concurrent Chemoradiotherapy</arm_group_label>
    <arm_group_label>Toripalimab Combined with Induction Chemotherapy Followed by Radiotherapy Alone</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18 to 65;&#xD;
&#xD;
          2. Pathological type: non-keratinizing carcinoma (World Health Organization criteria);&#xD;
&#xD;
          3. Diagnosed with LANPC (T4N1, T1-4N2-3) according to the 8th edition clinical staging&#xD;
             system of the American Joint Committee on Cancer [AJCC]/Union for International Cancer&#xD;
             Control [UICC];&#xD;
&#xD;
          4. ECOG performance score: 0 to 1;&#xD;
&#xD;
          5. Normal bone marrow function: white blood cell count &gt; 4×109/L, hemoglobin &gt; 90g/L,&#xD;
             platelet count &gt; 100×109/L;&#xD;
&#xD;
          6. Normal values of thyroid function, amylase and lipase examination, pituitary function,&#xD;
             inflammation and infection indicators, myocardial enzymes, and ECG results. For&#xD;
             patients older than 50 years with a smoking history, normal lung function are&#xD;
             required. Patients with abnormal ECG and/or a history of vascular disease (but not&#xD;
             meeting the exclusion criteria listed in the exclusion criteria 7) need further&#xD;
             testing and require normal results of myocardial function and color Doppler&#xD;
             ultrasound.&#xD;
&#xD;
          7. Normal liver and kidney function: total bilirubin ≤ 1.5 × upper limit of normal (ULN);&#xD;
             alanine transaminase and aspartate transaminase ≤ 2.5 × ULN; alkaline phosphatase ≤&#xD;
             2.5 × ULN; creatinine clearance rate ≥ 60 ml/min;&#xD;
&#xD;
          8. Patients must sign informed consent and be willing and able to comply with the&#xD;
             requirements of visits, treatment, laboratory tests and other research requirements&#xD;
             stipulated in the research schedule;&#xD;
&#xD;
          9. Subjects with pregnancy ability must agree to use reliable contraceptive measures from&#xD;
             screening to 1 year after treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hepatitis B virus surface antigen (HBsAg) positive and HBV DNA &gt; 1×10E3 copies/ml;&#xD;
             anti-hepatitis C virus positive;&#xD;
&#xD;
          2. Anti-human immunodeficiency virus (HIV) positive or diagnosed with acquired immune&#xD;
             deficiency syndrome (AIDS);&#xD;
&#xD;
          3. Active tuberculosis: active tuberculosis in the past 1 year should be excluded&#xD;
             regardless with treatment; history of active tuberculosis over 1 year should be&#xD;
             excluded except that previous regulatory anti-tuberculosis treatment is proved;&#xD;
&#xD;
          4. Active, known or suspected autoimmune disease (including but not limited to uveitis,&#xD;
             enteritis, hepatitis, pituitary, nephritis, vasculitis, hyperthyroidism,&#xD;
             hypothyroidism and asthma requiring bronchiectasis). Exceptions are type I diabetes&#xD;
             mellitus, hypothyroidism requiring hormone replacement therapy, skin disorders&#xD;
             requiring no systemic treatment (such as vitiligo, psoriasis or alopecia);&#xD;
&#xD;
          5. Previous interstitial lung disease or pneumonia requiring oral or intravenous steroid&#xD;
             therapy;&#xD;
&#xD;
          6. Chronic treatment with systemic glucocorticoid (dose equivalent to or over 10 mg&#xD;
             prednisone per day) or any other form of immunosuppressive therapy. Subjects who used&#xD;
             inhaled or topical corticosteroids were eligible;&#xD;
&#xD;
          7. Uncontrolled heart disease, for example: 1) heart failure (NYHA level ≥ 2); 2)&#xD;
             unstable angina; 3) myocardial infarction in past 1 year; 4) supraventricular or&#xD;
             ventricular arrhythmia requiring treatment or intervention;&#xD;
&#xD;
          8. Pregnant or lactating women (pregnancy test should be considered for women with sexual&#xD;
             life and fertility);&#xD;
&#xD;
          9. Previous or concurrent with other malignant tumors, except for adequately treated&#xD;
             non-melanoma skin cancer, cervical carcinoma in situ and thyroid papillary cancer;&#xD;
&#xD;
         10. Allergy to macromolecular protein preparations, or any component of nivolumab;&#xD;
&#xD;
         11. Active infection requiring systemic treatment;&#xD;
&#xD;
         12. Receiving live vaccine within 30 days of the initial nivolumab;&#xD;
&#xD;
         13. History of organ transplantation;&#xD;
&#xD;
         14. History of psychotropic disease, alcoholism or drug abuse; other situation assessed by&#xD;
             the investigators that may compromise the safety or compliance of patients, such as&#xD;
             serious disease requiring timely treatment (including mental illness), severe&#xD;
             laboratory abnormalities, or family-social risk factors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Ma, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Ma, M.D.</last_name>
    <phone>+862087343469</phone>
    <email>majun@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheng Xu, M.D.</last_name>
    <phone>+862087343500</phone>
    <email>xucheng@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shao-Wen Xiao, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First People's Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ning Zhang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panyu central hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guo-Rong Zhou, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiao-Dong Zhu, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Feng Jin, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hubei Province Cancer Hosiptal</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>De-Sheng Hu, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guang-Yuan Hu, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Kun-Yu Yang, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liang-Fang Shen, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Province Cancer Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jin-Gao Li, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Province Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiao-Zhong Chen, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, Ma J. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19;381(12):1124-1135. doi: 10.1056/NEJMoa1905287. Epub 2019 May 31.</citation>
    <PMID>31150573</PMID>
  </results_reference>
  <results_reference>
    <citation>Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27. Erratum in: J Clin Oncol. 2018 Aug 1;36(22):2360.</citation>
    <PMID>29584545</PMID>
  </results_reference>
  <results_reference>
    <citation>Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, Thanigaimani P, Cheng JD, Hansen AR. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol. 2017 Dec 20;35(36):4050-4056. doi: 10.1200/JCO.2017.73.3675. Epub 2017 Aug 24.</citation>
    <PMID>28837405</PMID>
  </results_reference>
  <results_reference>
    <citation>Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, Zhang Y, Chen L, Zhou N, Zhao Y, Hou X, Yang Q, Zhang L. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018 Oct;19(10):1338-1350. doi: 10.1016/S1470-2045(18)30495-9. Epub 2018 Sep 10.</citation>
    <PMID>30213452</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, Liao W, Jiang Y, Lin XY, Zhang QY, Yuan XL, Huang HX, Chen Y, Dai GH, Shi JH, Shen L, Yang SJ, Shu YQ, Liu YP, Wang W, Wu H, Feng H, Yao S, Xu RH. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). J Clin Oncol. 2021 Mar 1;39(7):704-712. doi: 10.1200/JCO.20.02712. Epub 2021 Jan 25.</citation>
    <PMID>33492986</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jun Ma, MD</investigator_full_name>
    <investigator_title>Vice President of SYSUCC</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>Immune checkpoint inhibitor</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Concurrent cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Blocking</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

